Loading...
•
Dec 31, 2025
Soleno Therapeutics Q4 2025 Earnings Report
Soleno Therapeutics reported a profitable fourth quarter driven by the successful commercial launch of VYKAT XR.
Key Takeaways
Soleno Therapeutics achieved significant commercial success in Q4 2025, generating $91.7 million in revenue from VYKAT XR and reaching quarterly net income of $43.4 million. The company saw strong adoption with 1,250 total patient start forms since launch and expanded its prescriber base, while maintaining a robust cash position of over $500 million to support future international expansion and pipeline development.
VYKAT XR generated $91.7 million in net product revenue for the fourth quarter of 2025.
The company achieved quarterly net income of $43.4 million, a significant turnaround from a $56.0 million loss in the prior year period.
Commercial momentum remains strong with 1,250 total patient start forms received and 859 active patients on drug as of year-end.
Soleno ended the year with $506.1 million in cash, equivalents, and marketable securities after a $100 million share repurchase.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Soleno plans to leverage its U.S. commercial success to expand into international markets and broaden its clinical pipeline.
Positive Outlook
- Plans to pursue regulatory approval in the EU following the U.S. launch.
- Evaluation of DCCR for additional high-need rare diseases to expand the pipeline.
- Anticipated continued commercial momentum for VYKAT XR in the U.S.
- Strong balance sheet with over $500 million in liquidity to fund growth.
- Over 185 million lives covered provides a strong foundation for reimbursement.
Challenges Ahead
- Selling, general and administrative expenses are anticipated to increase.
- R&D expenditures will fluctuate based on clinical program timing and manufacturing projects.
- Obligation to pay $21.2 million in commercial milestones, with $7.0 million due in Q1 2026.
- Potential for increased costs related to international expansion.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...